Latest Mood stabilizers Stories

12 New Epilepsy Drugs Usher In 'Era Of Abundance'

2010-10-21 13:43:48

A dozen new epilepsy drugs are giving doctors and patients more options, but making treatment decisions more complex, a Loyola epilepsy specialist reports in the journal Neurologic Clinics."Clinicians practice in an era of abundance of anti-epileptic drugs," Dr. Jorge J. AsconapÃ© wrote. The new drugs provide "an opportunity to better meet the needs of more patients."AsconapÃ©'s article will appear in the November issue of Neurologic Clinics, now available online.Since...

Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market

2010-08-25 08:00:00

WALTHAM, Mass., Aug. 25 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar...

FDA: Aseptic Meningitis Risk with Use of Seizure Drug Lamictal

2010-08-12 10:46:00

SILVER SPRING, Md., Aug. 12 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned that the drug Lamictal (lamotrigine), approved to treat seizures and bipolar disorder, can cause aseptic meningitis, an inflammation of the protective membranes (meninges) that cover the brain and spinal cord not caused by bacterial infection. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The agency is working...

Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy

2010-06-14 08:00:00

MAPLE GROVE, Minn., June 14 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options. "The...

Reducing The Toxicity Of Lithium

2010-06-08 15:30:12

Lithium is the most effective treatment for bipolar disorder. However, its use is limited because of neurological side effects and a risk for overdose-induced toxicity. Many of the beneficial effects of lithium are mediated by its inhibition of GSK-3 proteins, but whether this is the mechanism underlying its negative effects has not been determined. However, Raquel GÃ³mez-Sintes and JosÃ© Lucas, at CSIC/UAM, Spain, have now delineated a molecular pathway by which chronic administration of...

Mylan Receives Approval for Generic Version of NeurontinÂ® Tablets

2010-06-04 10:18:00

PITTSBURGH, June 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Gabapentin Tablets USP, 600 mg and 800 mg, the generic version of Pfizer's NeurontinÂ® Tablets for the treatment of postherpetic neuralgia, a complication of shingles. The product will be distributed by Mylan Pharmaceuticals Inc....

Pitt Team Finds Commonly Used Seizure Drug Could Treat Severe Genetic Liver Disease

2010-06-03 17:20:13

The liver scarring of Î±1-antitrypsin (AT) deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures, according to findings from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine that will published in Science and are available online today through the Science Express website.Because the anti-seizure drug is familiar to...

Phenytoin As A Mood Stabilizer?

2010-03-29 10:42:33

Phenytoin is a well known antiepileptic agent widely used throughout the world. Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties. In a study published in the March 2010 issue of Experimental Biology and Medicine Veronica Mariotti and...

Study Identifies Best Treatment For Childhood Epilepsy

2010-03-14 10:56:06

OHSU Doernbecher Children's Hospital is part of largest-ever NIH-funded pediatric epilepsy clinical trial to examine which of 3 standard treatments is most effectiveOne of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.OHSU Doernbecher Children's Hospital is one of 32 comprehensive pediatric epilepsy centers nationwide selected to...

Newly-Published Study Reinforces Role of Antiepileptic Drug Vimpat(R) (lacosamide) (C-V) as an Add-on Treatment that Significantly Reduces Partial-onset Seizures in Adults with Epilepsy

2010-03-11 08:05:00

ATLANTA, March 11 /PRNewswire/ -- UCB today announced that the antiepileptic drug (AED) VimpatÂ® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia. This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration (FDA) in 2008 for use as an add-on therapy for the treatment of partial-onset seizures in people...